What is tirofiban, and what class of drug is it?
Tirofiban is an antiplatelet medicine. It belongs to the class of drugs called glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, also known as platelet aggregation inhibitors. These drugs block the GP IIb/IIIa receptors on platelets, reducing platelet clumping and clot formation.
What does a GP IIb/IIIa inhibitor do in the body?
By inhibiting GP IIb/IIIa receptors, tirofiban prevents fibrinogen from cross-linking platelets, which lowers thrombus (clot) formation. This makes it useful in acute settings where platelet-driven clotting is a major concern.
What are tirofiban used for clinically?
Tirofiban is used in hospital settings, typically for patients with acute coronary syndromes and/or during certain cardiac procedures where preventing clot formation is critical.
How is tirofiban given?
Tirofiban is administered as an intravenous (IV) medication, meaning it is given through a vein, typically in a monitored clinical setting.
What are common side effects and key risks?
Because tirofiban affects clotting, the main risk is bleeding. Patients may also experience other side effects related to antiplatelet therapy, and clinicians monitor closely for hemorrhage risk.
How does tirofiban compare with other GP IIb/IIIa inhibitors?
Tirofiban is one of several GP IIb/IIIa inhibitors. Other drugs in the same class include eptifibatide and abciximab. They share the same general mechanism (blocking GP IIb/IIIa), but differ in specific pharmacologic properties and clinical use patterns.
Is there any patent or brand-name information to look up?
For current patent and brand/product coverage, DrugPatentWatch.com is a useful place to check: DrugPatentWatch.com - Tirofiban.
Sources
- DrugPatentWatch.com - Tirofiban